9:53 AM
 | 
Jul 20, 2018
 |  BC Week In Review  |  Company News  |  Deals

Boehringer exercises option for Eureka's TCR-mimicking antibodies

Boehringer Ingelheim GmbH (Ingelheim, Germany) exercised a 2015 option to exclusively license human TCR-mimicking antibodies against an undisclosed cancer target from Eureka Therapeutics...

Read the full 92 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >